Generic drug: pegfilgrastim-cbqv

Brand name: Udenyca

What is Udenyca (pegfilgrastim-cbqv), and how does it work?

Udenyca (pegfilgrastim-cbqv) is a prescription medicine used to treat the symptoms of Hematopoietic Subsyndrome of Acute Radiation Syndrome and prevention of chemotherapy-induced Neutropenia. Udenyca may be used alone or with other medications.

Udenyca belongs to a class of drugs called Hematopoietic Growth Factors.

What are the side effects of Udenyca?

Udenyca may cause serious side effects including:

Get medical help right away, if you have any of the symptoms listed above.

The most common side effects of Udenyca include:

  • bone pain, and
  • pain in your arms or legs

Tell the doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Udenyca. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is the dosage for Udenyca?

Patients With Cancer Receiving Myelosuppressive Chemotherapy

The recommended dosage of Udenyca is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle. For dosing in pediatric patients weighing less than 45 kg, refer to Table 1. Do not administer Udenyca between 14 days before and 24 hours after administration of cytotoxic chemotherapy.

Administration

  • Udenyca is administered subcutaneously via a single-dose prefilled syringe for manual use.
  • Prior to use remove the carton from the refrigerator and allow the Udenyca prefilled syringe to reach room temperature for a minimum of 30 minutes. Discard any prefilled syringe left at room temperature for greater than 48 hours.
  • Visually inspect parenteral drug products (prefilled syringe) for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer Udenyca if discoloration or particulates are observed.
  • The needle cap on the prefilled syringe is not made with natural rubber latex.
Pediatric Patients Weighing Less Than 45 kg
  • The Udenyca prefilled syringe is not designed to allow for direct administration of doses less than 0.6 mL (6 mg).
  • The syringe does not bear graduation marks which are necessary to accurately measure doses of Udenyca less than 0.6 mL (6 mg) for direct administration to patients.
  • Thus, the direct administration to patients requiring dosing of less than 0.6 mL (6 mg) is not recommended due to the potential for dosing errors. Refer to Table 1.

Table 1: Dosing of Udenyca for pediatric patients weighing less than 45 kg

Body Weight Udenyca DoseVolume to Administer
Less than 10 kg*See below*See below*
10 - 20 kg1.5 mg0.15 mL
21 - 30 kgmg .5 2.0.25 mL
31 - 44 kgmg 40.4 mL
*For pediatric patients weighing less than 10 kg, administer 0.1 mg/kg (0.01 mL/kg) of Udenyca

SLIDESHOW

Skin Cancer Symptoms, Types, Images See Slideshow

What drugs interact with Udenyca?

No information provided

Is Udenyca safe to use while pregnant or breastfeeding?

  • Although available data with Udenyca or pegfilgrastim product use in pregnant women are insufficient to establish whether there is a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, there are available data from published studies in pregnant women exposed to filgrastim products. These studies have not established an association of filgrastim product use during pregnancy with major birth defects, miscarriage, or adverse maternal or fetal outcomes.
  • There are no data on the presence of pegfilgrastim products in human milk, the effects on the breastfed child, or the effects on milk production.
  • Other filgrastim products are secreted poorly into breast milk, and filgrastim products are not orally absorbed by neonates.
  • The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Udenyca and any potential adverse effects on the breastfed child from Udenyca or from the underlying maternal condition.

Summary

Udenyca (pegfilgrastim-cbqv) is a prescription medicine used to treat the symptoms of Hematopoietic Subsyndrome of Acute Radiation Syndrome and prevention of chemotherapy-induced Neutropenia. Serious side effects of Udenyca include hives, difficulty breathing, swelling of your face, lips, tongue, or throat; skin rash, sweating, dizziness, warmth or tingly feeling, wheezing, decreased urination, tiredness, lightheadedness, sudden swelling, and others.

Treatment & Diagnosis

Medications & Supplements

Prevention & Wellness

Health Solutions From Our Sponsors

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Medically Reviewed on 6/16/2021
References
All sections courtesy of the U.S. Food and Drug Administration